Impact News +++ Why FormFactor (FORM) Might be Well Poised for a Surge (Zacks) +++ FORMFACTOR Aktie +3,95%

VANDA Aktie

>VANDA Aktienkurs

4.89 EUR -3.4% (TradegateBSX)

Ask: 4.982 EUR / 3100 Stück

Bid: 4.876 EUR / 3100 Stück

Tagesumsatz: 570 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

VANDA Aktie über LYNX handeln

Intraday

1 Jahr

>VANDA Performance

1 Woche: +0,9%

1 Monat: -4,9%

3 Monate: -34,5%

6 Monate: -1,4%

1 Jahr: +32,2%

laufendes Jahr: -14,9%

>VANDA Aktie

Name:

VANDA PHARMACEUTICALS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US9216591084 / A0JJT3

Symbol/ Ticker:

VM4 (Frankfurt) / VNDA (NASDAQ)

Kürzel:

FRA:VM4, ETR:VM4, VM4:GR, NASDAQ:VNDA

Index:

Webseite:

https://www.vandapharma.c..

Profil:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapies addressing high unmet medical needs in areas such as sleep-wake disorders, psychiatric and neurologic conditions, motion sickness,..
>Volltext..

Marktkapitalisierung:

305.16 Mio. EUR

Unternehmenswert:

141.25 Mio. EUR

Umsatz:

188.27 Mio. EUR

EBITDA:

-127 Mio. EUR

Nettogewinn:

-207.08 Mio. EUR

Gewinn je Aktie:

-3.5 EUR

Schulden:

11.3 Mio. EUR

Liquide Mittel:

46.71 Mio. EUR

Operativer Cashflow:

-109.37 Mio. EUR

Bargeldquote:

1.49

Umsatzwachstum:

1.28%

Gewinnwachstum:

-406.92%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

VANDA

Letzte Datenerhebung:

15.06.26

>VANDA Kennzahlen

Aktien/ Unternehmen:

Aktien: 60.14 Mio. St.

Frei handelbar: 94.57%

Leerverk. Aktien: 11.33%

Rückkaufquote: -

Mitarbeiter: 533

Umsatz/Mitarb.: 0.35 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 125.54%

Bewertung:

KGV: -

KGV lG: -

KUV: 1.65

KBV: 1.34

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 89.91%

Gewinnmarge: -109.99%

Operative Marge: -73.64%

Managementeffizenz:

Gesamtkaprendite: -44.97%

Eigenkaprendite: -60.48%

>VANDA Peer Group

Gesundheit, Multiple Sklerose- Behandlung, Hauterkrankungen & -behandlung/ Dermatologie, Magen-Darm-Erkrankungen & -behandlung, Neurologische Erkrankungen/ Schlaganfälle
>Alle Branchen..

>VANDA Chart & Kurs - NASDAQ

>VANDA News

15.06.26 - 19:24	Mag 7 is no more, meet the FAB 10: Retail investors buy SpaceX in record numbers for their new portfolio plan (CNBC)
	Single-stock retail buying was $117 million for SpaceX on its first day of trading, amounting to 56% of all retail purchases, Vanda Research found....

12.06.26 - 15:01	KI-Aktien raus, SpaceX rein? Privatanleger bereiten sich offenbar auf Mega-IPOs vor (Business Insider DE)
	Privatanleger verkaufen laut Vanda Research zuletzt KI-Favoriten und bauen Cash auf. Grund könnte der bevorstehende Börsengang von SpaceX sein....

10.06.26 - 22:06	Equity positioning sees sharpest unwind in 15 years as AI trade cracks - Vanda (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

09.06.26 - 15:33	SpaceX IPO buzz drives retail buying of space stocks, Vanda says (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.05.26 - 13:03	Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis (PR Newswire)
	WASHINGTON, May 27, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to imsidolimab, a high‑affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody,......

18.05.26 - 21:57	Elon Musk′s Tesla Army Faces Space X IPO: Will Capital Rotate From TSLA Into SPCX? (Benzinga)
	Wall Street warns the SpaceX IPO may split Tesla's pro-Musk retail base. Vanda data shows TSLA has drawn just $1 million in net retail inflows since the listing was confirmed. Importance Rank: 1 read more...

12.05.26 - 22:18	Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire EN)
	SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported financial results for the first quarter ended March 31, 2026, and provided a business update....

12.05.26 - 16:01	Earnings Call Transkript: Vanda Pharmaceuticals verfehlt EPS-Prognose für Q1 2026, Aktie fällt (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

11.05.26 - 15:18	Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors (GlobeNewswire EN)
	SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced the appointment of Christopher Murphy as Chief Financial Officer and Owen Hughes as a member of its Board of Directors....

08.05.26 - 00:45	Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences (PR Newswire)
	WASHINGTON, May 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in May 2026: The Bank of America Securities Global Health Care Conference 2026 in Las Vegas, Nevada on......

07.05.26 - 11:06	Vanda targets $240M-$290M 2026 revenue as it introduces $10M-$30M NEREUS sales outlook (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.05.26 - 01:00	Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
	Vanda (VNDA) delivered earnings and revenue surprises of -54.72% and -9.58%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?...

07.05.26 - 00:36	Vanda (VNDA) Q1 2026 Earnings Call Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

06.05.26 - 22:06	Vanda Pharmaceuticals GAAP EPS of -$0.82 misses by $0.13, revenue of $51.7M misses by $1.2M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.05.26 - 22:03	Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results (PR Newswire)
	Fanapt® net product sales rose 26% to $29.6 million; total prescriptions increased 32% and new-to-brand prescriptions surged 76% NEREUS™ (tradipitant) launched via nereus.us, an innovative direct-to-consumer platform – the first new prescription medicine in more than 40 years for the......

05.05.26 - 17:30	Wall Street Analysts Predict a 105.03% Upside in Vanda (VNDA): Here′s What You Should Know (Zacks)
	The mean of analysts' price targets for Vanda (VNDA) points to a 105% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock....

04.05.26 - 22:18

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference (GlobeNewswire EN)

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Daniel Faga, president and chief executive officer of Anaptys, is scheduled to participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on Wednesday, May 6, 2026. The fireside chat is scheduled to begin at 1:30pm ET....

04.05.26 - 21:48	Kursanstieg bei Atossa Genetics: Verwechslung mit Vanda Pharmaceuticals vermutet (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

01.05.26 - 23:45	Vanda rises after hours on launch of tradipitant for motion sickness (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

01.05.26 - 22:39	Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years (PR Newswire)
	Consumers can now order NEREUS™ directly at nereus.us WASHINGTON, May 1, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant) is now commercially available across the United States for the prevention of vomiting induced by......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Schlagworte sind Kommandos der Dummheit. - Hans Lohberger

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram